advertisement
Grus FH 10
Showing records 1 to 10 | Display all abstracts from Grus FH106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Tonner H
International journal of molecular sciences 2022; 23:
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Fomo KN; Schmelter C
Frontiers in medicine 2022; 9: 993351
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Hunn S
International journal of molecular sciences 2022; 23:
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Atta J
Frontiers in medicine 2022; 9: 993351
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Auler N; Schmelter C
International journal of molecular sciences 2022; 23:
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Beutgen VM; Beutgen VM; Schwarz R
Frontiers in medicine 2022; 9: 993351
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Pfeiffer N
International journal of molecular sciences 2022; 23:
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Perumal N
Frontiers in medicine 2022; 9: 993351
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Grus FH
International journal of molecular sciences 2022; 23:
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Govind G; Speck T; Pfeiffer N; Grus FH
Frontiers in medicine 2022; 9: 993351
